Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

Genestreti G., Tiseo M., Kenmotsu H., Kazushige W., Di Battista M., Cavallo G., ...Daha Fazla

CLINICAL LUNG CANCER, cilt.16, sa.6, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier


Small-cell lung cancer has a high chemotherapeutic sensitivity but with disappointing outcome results. Patients with "sensitive disease" are those who respond to treatment with a long relapse-free interval (RFI): in these cases rechallenge with first-line chemotherapy might represent a therapeutic opportunity. Our largest retrospective experience confirmed that rechallenge is feasible with interesting outcome results; there are no statistical differences between RFI and outcome.